Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m

Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.

This article is for Legal Business subscribers. Please log in or subscribe to read on.

Related Content

Trading Places: Sidley continues funds and finance build while Milbank grows its new Chicago office

Global elite firms advise on €10.8bn EQT-QIAGEN deal

‘He’s stuck his neck out’ – national law firm leaders size up Burnham’s devolution drive

Ropes makes up four London partners in first City promotions since 2023

Latham makes up 36 partners, with none outside US and EU

US firms lead as LSEG acquires Octus from Permira for $3.5bn

Dealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega deal

Dealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loan

Deal Watch: activity powers on as Latham and A&O lead on $19bn energy joint venture